迟亚云 副研究员 副研究员，博士 E-mail: yychi@126.com

　　2005年毕业于复旦大学上海医学院获得医学学士学位，2010年毕业于复旦大学上海医学院基础医学院获生物化学与分子生物学博士学位，毕业后任职于复旦大学附属肿瘤医院肿瘤研究所，乳腺癌研究所。期间于2014-2015年前往美国田纳西大学癌症研究中心访问交流。主持多项国家自然科学基金青年项目和面上项目，参加国家重点基础研究发展计划、上海市科委基础研究项目等。研究成果发表于Oncogene, Theranostics，Journal of Biological Chemistry等国际核心杂志。

研究领域：

　　乳腺肿瘤耐药及侵袭转移的分子机制和转化性研究
　　1．HER2阳性乳腺癌治疗敏感性的多组学研究；
　　2．乳腺癌转移侵袭相关分子标志物的筛选及机制研究；
　　3．乳腺癌耐药及预后相关的分子模型建立及研究。

代表性论著：

1.   Yayun Chi^#, Jingyan Xue#, Sheng Huang#, Bingqiu Xiu#, Yonghui Su, Wei Wang, Rong Guo, Lei Wang, Lun Li, Zhiming Shao, Wei Jin, Zhaohui Wu*, Jiong Wu*. CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50. Theranostics.  doi:10.7150/thno.36338.

2.   Sheng Huang^#, Yayun Chi^#, Yi Qin^#, Ziliang Wang, Bingqiu Xiu, Yonghui Su, Rong Guo, Liang Guo, Hefen Sun, Chujia Zeng, Shuling Zhou, Xin Hu, Sheng Liu, Zhimin Shao, Zhaohui Wu, Wei Jin, Jiong Wu*. CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. Theranostics, 2018; 8(9): 2549-2564.

3.   Lei Liu^#, Yayun Chi^#, Jiajian Chen, Jingyan Xue, Linlin Deng, Naisi Huang, Jianghua Shao & Jiong Wu*. Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2−subtype breast cance. Sci Rep, 2017 Sep 28; 7(1):12382.

4.    Xue J^#, Chi Y^#, Chen Y, Huang S, Ye X, Niu J, Wang W, Pfeffer LM, Shao ZM, Wu ZH, Wu J: MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene, 2016 Jan 28; 35(4):448-58.

5.    Chi Y^#, Huang S^#, Liu M, Guo L, Shen X, Wu J. Cyclin D3 predicts disease-free survival in breast cancer. Cancer Cell Int, 2015 Sep 26; 15:89.

6.    Chi Y^#, Huang S^#, Peng H, Liu M, Zhao J, Shao Z, Wu J. Critical role of CDK11(p58) in human breast cancer growth and angiogenesis. Bmc Cancer, 2015 Oct 15; 15:701.

7.    Huang S^#, Kou B^#, Chi Y^#, Xi Y, Cao Y, Cui W, Hu X, Shao Z, Guo H, Fu Y et al. In-line phase-contrast and grating-based phase-contrast synchrotron imaging study of brain micrometastasis of breast cancer. Sci Rep, 2015 Mar 30; 5:9418.

8.   Chi Y^#, Huang S^#, Liu M, Huang N, Zhou S, Zhou B, Wu J. Role of BC040587 as a predictor of poor outcome in breast cancer. Cancer Cell Int, 2014 Nov 26; 14(1):123.

9.   Chi Y^#, Huang S^#, Wang L, Zhou R, Wang L, Xiao X, Li D, Cai Y, Zhou X, Wu J. CDK11p58 inhibits ERalpha-positive breast cancer invasion by targeting integrin beta3 via the repression of ERalpha signaling. BMC Cancer, 2014 Aug 8; 14:577.

10.  Chi Y, Wang L, Xiao X, Wei P, Wang Y, Zhou X. Abnormal expression of CDK11p58 in prostate cancer. Cancer Cell Int, 2014 Jan 8; 14(1):2.

11.  Chi Y^#, Zhang C^#, Zong H, Hong Y, Kong X, Liu H, Zou W, Wang Y, Yun X, Gu J: Thr-370 is responsible for CDK11(p58) autophosphorylation, dimerization, and kinase activity. J Biol Chem, 2011 Jan 21; 286(3):1748-57.